Attendee search 

The founder team of PreOmics started working on optimized LC-MS proteomic workflows at the Matthias Mann lab in 2010. After establishing an optimized and easier sample preparation process in 2014, Dr. Nils A. Kulak together with Dr. Garwin Pichler set forth to validate their technologies with external laboratories and researchers. With a lot of support of proteomics experts, engineers and industry designers, they made their first product ready-for-market. The PreOmics team won several awards for their business idea, were supported by various accelerator programs and established their company in the beginning of 2016. They are now located at the IZB in Martinsried just south of Munich.
We empower our clients in life science to establish biological knowledge through efficient reliable solutions and workflows that set the standard for protein analysis. Our team spirit, energy and commitment empower us to be creative and quality focused. A trusted partner with deeply rooted scientific experience.

Trove is a semi-virtual biotech start-up located in Rockville, Maryland, USA, developing an advanced biologic asset and seeking funding and partners to conduct clinical trials in respiratory disease. We have data and drug supply on our lead, clinical-stage biologic asset to support up to 3 clinical trials in different respiratory conditions (2 x Phase 1b/2a in COVID and lung transplant; and 1 x Phase 2 in chronic sinusitis). Our biologic, called Therabron, is a replacement for a normally abundant native protein that is deficient in our targeted indications. Replacement therapies have a high approval rate with FDA (>70%) and patients with genetic deficiencies can be selected in some trials to increase our chances of demonstrating efficacy. Therabron was safe in 3 early studies. At present, the quickest path to an approval is likely an Emergency Use Authorization in severe COVID-19 patients, so we're looking for an initial $2M seed/Series A round to fund a Phase 1b/2a clinical trial then need another $16M to produce more drug and perform a convincing Phase 2 trial. We are already talking to several potential corporate partners, have signed one CDA with a top 5 pharma, and a relatively small amount of investment in clinical proof of concept demonstrations will attract at least one partner. Once clinical POC is established in targeted indications, we plan to exit via sale/acquisition or out-license. Our markets are large (3 products x >$1B each US) and deal comps in the respiratory space are $250M each and up. We can maximize our ROI by out-licensing the first indication and re-investing upfront license payment proceeds to advance the drug in further indications, depending on what happens in each field/indication and what we (management team and investors) decide to do.

iNNOGING Medical - Remote and offline ultrasound image analysis solution

Ultrasound is a real-time examination and very much operator dependent.
Majority of ultrasound scans are done by technicians and afterwards diagnosed off-line by the expert without the presence of the patient. A major drawback is that the radiologist who determines the diagnoses is not the person who performs the ultrasound scan; hence this workflow might lead to errors and worse to misdiagnoses.
iNNOGING is developing a technology that will provide the radiologists a remote and off-line tool to inspect areas of interest, based on recorded ultrasound scans. Allowing navigation like in real time as if the patient is there with the doctor, while all possible information (any plane) of an organ is visible, even information that was not presented in the original scan.

In addition to the above, we have recently launched an affordable SaaS based Ultrasound Simulator.

SOTIO is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. SOTIO’s robust clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, a platform to streamline personalized active immune cell therapies and a new generation of potent and stable antibody-drug conjugates (ADCs).
Sotio is developing the next generation of potent immunotherapies for patients with cancer. The Company is building its pipeline of attractive oncology programs by pursuing promising early stage candidates backed by strong science through strategic licensing, M&A and in-house discovery efforts. Sotio’s scientific research, translational and clinical development expertise provides the infrastructure to translate early stage science into promising clinical stage assets.

Curon Biopharmaceutical, founded in June 2018, is a biopharma company with facility in Shanghai focusing on developing next generation anti-cancer therapies. It completed a $150 million USD Series A financing led by 6 Dimensions Capital, Boyu Capital, and Temasek. With its internationally experienced senior executive management team, Curon Biopharma currently holds multiple promising novel cancer immuno-therapeutic agents in its pipeline and is committed to bring next generation cancer immunotherapies to patients. Curon strives to accelerate its pipeline assets clinical development, further expand its portfolio through in-licensing and other forms of collaboration with biotech and pharmaceutical companies around the world to bring more effective treatment options to patients.

Drive Therapeutics is developing a novel, long acting, bispecific nucleic acid therapeutic to block the angiogenesis, inflammation, and fibrosis underlying retinal disease. Drive’s lead program is a bispecific aptamer therapeutic made up of two well validated components: a pan-specific anti-VEGF-A aptamer and an anti-Interleukin-8 (IL8) aptamer. Drive’s lead program will mitigate poor patient response to existing anti-VEGF therapy, improve outcomes and reduce patient burden. By targeting both angiogenesis and a critical immune pathway that drives both inflammation and angiogenesis, Drive’s bispecific inhibitor is the key to overcoming the limitations of VEGF monotherapy. In addition to current candidates, Drive’s aptamer therapeutic discovery platform will allow for streamlined, efficient development of new therapies to pathologically relevant ophthalmologic targets.

Articulate Labs builds wearable medical devices amplify muscle growth throughout everyday activity to help others conquer functional limitations and to restore physical capability

The Telocyte Mission:
The use of innovative advanced regenerative cell and gene therapies to reset the cell senescence that underlies and defines the "aging process". Cell senescence instigates a cascade of pathology that causes age- related disease, as our telomeres shorten and modulate the changing pattern of gene expression – the epigenetic signalling information – in aging cells. This is the fundamental problem of aging and age-related disease. To be effective, national healthcare systems need to support the ability to maintain normal cell function as we age, both preventing age-related disease and lowering healthcare costs
Our first clinical target is Alzheimer’s disease.

REM Analytics is a research and development service organisation, helping our customers develop and commercialise new products fast.
Having developed a series of core proprietary technologies, we deploy them to guarantee our customers the shortest time from concept to market. Our areas of focus are the development of personalised nutrition solutions, active food ingredients, functional cosmetics and agriculture.